Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5

다국어 초록 (Multilingual Abstract)

Tumor necrosis factor-related apoptosis-induced ligand (TRAIL) induces apoptosis selectively in cancer cells while sparing normal cells. However, many cancer cells are resistant to TRAIL-induced cell death.
Here, we report that paxilline, an indole alkaloid from Penicillium paxilli, can sensitize various glioma cells to TRAIL-mediated apoptosis. While treatment with TRAIL alone caused partial processing of caspase-3 to its p20 intermediate in TRAIL-resistant glioma cell lines, co-treatment with TRAIL and subtoxic doses of paxilline caused complete processing of caspase-3 into its active subunits. Paxilline treatment markedly upregulated DR5, a receptor of TRAIL, through a CHOP/GADD153-mediated process. In addition, paxilline treatment markedly downregulated the protein levels of the short form of the cellular FLICE-inhibitory protein (c-FLIPS) and the caspase inhibitor, survivin,through proteasome-mediated degradation. Taken together,these results show that paxilline effectively sensitizes glioma cells to TRAIL-mediated apoptosis by modulating multiple components of the death receptor-mediated apoptotic pathway. Interestingly,paxilline/TRAIL co-treatment did not induce apoptosis in normal astrocytes, nor did it affect the protein levels of CHOP, DR5 or survivin in these cells. Thus, combined treatment regimens involving paxilline and TRAIL may offer an attractive strategy for safely treating resistant gliomas.

참고문헌 (Reference)

1 Knaus HG, "Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium- activated potassium channels" 33 : 5819-5828, 1994

2 Kaddour-Djebbar I, "Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer" 5 : 1958-1966, 2006

3 Lefranc F, "The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas" 10 : 198-206, 2008

4 Altieri DC, "The molecular basis and potential role of survivin in cancer diagnosis and therapy" 7 : 542-547, 2001

5 Bilmen JG, "The mechanism of inhibition of the sarco/endoplasmic reticulum Ca2+ ATPase by paxilline" 406 : 55-64, 2002

6 Sohn J, "The effect of ursodeoxycholic acid on the survivin in thapsigargin-induced apoptosis" 191 : 83-92, 2003

7 Coiret G, "The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells" 71 : 843-851, 2007

8 Huang L, "Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone" 34 : 971-981, 2004

9 Lytton J, "Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps" 266 : 17067-17071, 1991

10 Kim EH, "Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP" 24 : 6877-6889, 2005

11 Ashkenazi A, "Safety and antitumor activity of recombinant soluble Apo2 ligand" 104 : 155-162, 1999

12 Tiwary R, "Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis" 5 : 11865-, 2010

13 Weaver AK, "Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells" 78 : 224-234, 2004

14 Monteith GR, "Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport" 7 : 519-530, 2007

15 Galvez A, "Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus" 265 : 11083-11090, 1990

16 Yoshida T, "Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/Enhancer-binding protein homologous protein" 65 : 5662-5667, 2005

17 Yin LT, "Potential biochemical therapy of glioma cancer" 362 : 225-229, 2007

18 Sanchez M, "Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel" 35 : 963-968, 1996

19 Kim SU, "Neuroimmunology of gangliosides in human neurons and glial cells in culture" 15 : 303-321, 1986

20 Bloch M, "KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer" 26 : 2525-2534, 2007

21 Irmler M, "Inhibition of death receptor signals by cellular FLIP" 388 : 190-195, 1997

22 Hao C, "Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells" 61 : 1162-1170, 2001

23 Kato J, "Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy" 95 : 92-95, 2001

24 He Q, "Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway" 21 : 2623-2633, 2002

25 Goeger DE, "Cyclopiazonic acid inhibition of the Ca2+-transport ATPase in rat skeletal muscle sarcoplasmic reticulum vesicles" 37 : 978-981, 1988

26 Berenbaum MC, "Criteria for analyzing interactions between biologically active agents" 35 : 269-335, 1981

27 Sheridan JP, "Control of TRAILinduced apoptosis by a family of signaling and decoy receptors" 277 : 818-821, 1997

28 Kovacs GG, "Changes in intracellular Ca2+ and pH in response to thapsigargin in human glioblastoma cells and normal astrocytes" 289 : 361-371, 2005

29 Weller RO, "Brain tumors in man" 24 : 91-98, 1986

30 Kischkel FC, "Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5" 12 : 611-620, 2000

31 Ziegler DS, "Anti-apoptosis mechanisms in malignant gliomas" 26 : 493-500, 2008

32 Ambrosini G, "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma" 3 : 917-921, 1997